Clinical Trial: CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: CEV With/Without Periocular Carboplatin Chemotherapy for Nonmetastatic Extraocular Retinoblastoma Carboplatin--A Single Center, Retrospective Study to Evaluate the Efficac

Brief Summary: This study will evaluate a uniform chemotherapy protocol for nonmetastatic extraocular retinoblastoma

Detailed Summary: This study will be a phase 4 open label interventional case series. Patients with retinoblastoma will be receive chemotherapy with or without periocular injections of carboplatin at a dose of 20mg/2 ml. Patients will receive chemotherapy on a monthly basis for a total duration of therapy of 6 months. Patients will be followed for 18 months .
Sponsor: Sun Yat-sen University

Current Primary Outcome: Event Free Survival Rate [ Time Frame: 18 months ]

measure the event free survival rate for the patients at 18 months: patients that without tumor relapse or metastasis


Original Primary Outcome: Event Free Survival Rate [ Time Frame: 18 months ]

measure theevent free survival rate for the patients at 18 months


Current Secondary Outcome:

Original Secondary Outcome:

Information By: Sun Yat-sen University

Dates:
Date Received: December 15, 2014
Date Started: January 2009
Date Completion:
Last Updated: March 11, 2015
Last Verified: March 2015